Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 603

1.

Cardiovascular manifestations of sickle cell disease.

Hammoudi N, Lionnet F, Redheuil A, Montalescot G.

Eur Heart J. 2019 Apr 21. pii: ehz217. doi: 10.1093/eurheartj/ehz217. [Epub ahead of print]

PMID:
31005979
2.

Correction.

Overtchouk P, Guedeney P, Rouanet S, Verhoye JP, Lefevre T, Van Belle E, Eltchaninoff H, Gilard M, Leprince P, Iung B, Barthelemy O, Le Breton H, Souteyrand G, Vicaut E, Montalescot G, Collet JP.

J Am Coll Cardiol. 2019 Apr 16. pii: S0735-1097(19)34817-X. doi: 10.1016/j.jacc.2019.04.010. [Epub ahead of print] No abstract available.

PMID:
31002877
3.

Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach.

Lattuca B, Kerneis M, Zeitouni M, Cayla G, Guedeney P, Collet JP, Montalescot G, Silvain J.

Drugs Aging. 2019 Apr 5. doi: 10.1007/s40266-019-00663-y. [Epub ahead of print] Review.

PMID:
30953328
4.

Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.

Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP.

Am Heart J. 2019 Mar 1;212:13-22. doi: 10.1016/j.ahj.2019.02.006. [Epub ahead of print]

PMID:
30928824
5.

Kidney in the transformation matrix.

Kerneis M, Silvain J, Montalescot G.

Eur Heart J. 2019 Apr 14;40(15):1233-1235. doi: 10.1093/eurheartj/ehz088. No abstract available.

PMID:
30879031
6.

Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation.

Palmerini T, Bruno AG, Gilard M, Morice MC, Valgimigli M, Montalescot G, Collet JP, Della Riva D, Bacchi-Reggiani ML, Steg PG, Diallo A, Vicaut E, Helft G, Nakamura M, Généreux P, Vahl TP, Stone GW.

Circ Cardiovasc Interv. 2019 Mar;12(3):e007541. doi: 10.1161/CIRCINTERVENTIONS.118.007541.

PMID:
30871353
7.

Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction?

Zeitouni M, Kerneis M, Lattuca B, Guedeney P, Cayla G, Collet JP, Montalescot G, Silvain J.

Am J Cardiovasc Drugs. 2019 Mar 4. doi: 10.1007/s40256-019-00338-4. [Epub ahead of print] Review.

PMID:
30828768
8.

Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction.

Silvain J, Rakowski T, Lattuca B, Liu Z, Bolognese L, Goldstein P, Hamm C, Tanguay JF, Ten Berg J, Widimsky P, Miller D, Portal JJ, Collet JP, Vicaut E, Montalescot G, Dudek D; ACCOAST Investigators.

J Am Coll Cardiol. 2019 Mar 5;73(8):906-914. doi: 10.1016/j.jacc.2018.11.055.

PMID:
30819358
9.

Anticoagulation, the Unknown of the Antithrombotic Equation After Stenting of an Acute Coronary Syndrome.

Montalescot G, Angiolillo DJ.

J Am Coll Cardiol. 2019 Feb 26;73(7):775-778. doi: 10.1016/j.jacc.2018.12.022. No abstract available.

PMID:
30784670
10.

Interventional Standby for CABG Surgery: The Reverse Paradigm.

Guedeney P, Montalescot G.

J Am Coll Cardiol. 2019 Feb 5;73(4):424-426. doi: 10.1016/j.jacc.2018.11.023. No abstract available.

PMID:
30704574
11.

Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as biomarkers of acute kidney injury after ST-segment elevation myocardial infarction treated by percutaneous coronary intervention.

Nguyen LS, Spagnoli V, Kerneis M, Hauguel-Moreau M, Barthélémy O, Collet JP, Montalescot G, Silvain J.

Arch Cardiovasc Dis. 2019 Mar;112(3):180-186. doi: 10.1016/j.acvd.2018.11.006. Epub 2019 Jan 9.

PMID:
30639197
12.

The false illusion of coronary thrombus device-management.

Lattuca B, Montalescot G.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4117-S4121. doi: 10.21037/jtd.2018.10.25. No abstract available.

13.

Head-to-head comparison of the diagnostic performances of Rubidium-PET and SPECT with CZT camera for the detection of myocardial ischemia in a population of women and overweight individuals.

Hyafil F, Chequer R, Sorbets E, Estellat C, Ducrocq G, Rouzet F, Alfaiate T, Regaieg H, Abtan J, Leygnac S, Milliner M, Imbert L, Burg S, Ben Azzouna R, Potier L, Laouénan C, Quintin C, Roussel R, Hartemann A, Montalescot G, Marie PY, Steg G, Le Guludec D.

J Nucl Cardiol. 2018 Dec 20. doi: 10.1007/s12350-018-01557-z. [Epub ahead of print]

PMID:
30574676
14.

A farewell to aspirin in primary prevention?

Montalescot G.

Nat Rev Cardiol. 2019 Feb;16(2):76-77. doi: 10.1038/s41569-018-0148-z. No abstract available.

PMID:
30573760
15.

Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction.

Guerin M, Silvain J, Gall J, Darabi M, Berthet M, Frisdal E, Hauguel-Moreau M, Zeitouni M, Kerneis M, Lattuca B, Brugier D, Collet JP, Lesnik P, Montalescot G.

J Am Coll Cardiol. 2018 Dec 25;72(25):3259-3269. doi: 10.1016/j.jacc.2018.09.080.

PMID:
30573028
16.

Left Atrial Appendage Closure in Atrial Fibrillation.

Fauchier L, Cinaud A, Brigadeau F, Lepillier A, Pierre B, Gras D, Mansourati J, Deharo JC, Montalescot G, Defaye P.

J Am Coll Cardiol. 2018 Dec 4;72(22):2806-2807. doi: 10.1016/j.jacc.2018.08.2196. No abstract available.

PMID:
30497568
17.

Coronary Artery Bypass Graft Surgery Guided by FFR: Fraction of the Final Response.

Montalescot G, Lattuca B.

J Am Coll Cardiol. 2018 Dec 4;72(22):2744-2746. doi: 10.1016/j.jacc.2018.09.036. No abstract available.

PMID:
30497560
18.

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators.

N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.

PMID:
30403574
19.

One-Year Survival After ST-Segment-Elevation Myocardial Infarction in Relation With Prehospital Administration of Dual Antiplatelet Therapy.

Danchin N, Puymirat E, Cayla G, Cottin Y, Coste P, Gilard M, Goldstein P, Braun F, Belle L, Montalescot G, Ferrières J, Schiele F, Simon T; FAST-MI Investigators.

Circ Cardiovasc Interv. 2018 Sep;11(9):e007241. doi: 10.1161/CIRCINTERVENTIONS.118.007241.

PMID:
30354592
20.

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine.

Lapostolle F, Van't Hof AW, Hamm CW, Stibbe O, Ecollan P, Collet JP, Silvain J, Lassen JF, Heutz WMJM, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Ten Berg J, Zeymer U, Licour M, Tsatsaris A, Montalescot G; ATLANTIC Investigators.

Am J Cardiovasc Drugs. 2019 Apr;19(2):173-183. doi: 10.1007/s40256-018-0305-0.

PMID:
30353444

Supplemental Content

Loading ...
Support Center